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MUCOCUTANEOUS  MANIFESTATIONS  IN  PATIENTS RECEIVING  
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BACKGROUND: 
 Chemotherapy is a common, widely used treatment for cancer. 
Cutaneous adverse drug reactions (CADRs) are the most commonly associated 
adverse effects with chemotherapy next to haematological toxicity. They range 
from mild reactions to severe fatal reactions. Pattern  of  adverse  cutaneous  
reactions  to  chemotherapeutic  drugs  is  changing  every  year. Hence  this  
study  was  conducted  to study  the  pattern  of  adverse  drug  reactions  
following  cancer  chemotherapy. 
AIM: 
To estimate and describe the mucocutaneous adverse effects of cancer 
chemotherapeutics agents. 
MATERIALS AND METHODS: 
      This is an Observational prospective study done during the period from 
March 2017 to September 2018.      
 
 
RESULTS: 
Total incidence of CADRs - 35%. Most common malignancy observed 
was carcinoma breast (46.7%) which was frequently encountered with CADRs, 
followed by carcinoma of lung (11.4%), ovary and colon (each 8.6%). Most 
frequently used regimen was Taxanes/Doxorubicin/ Cyclophosphamide and 
Doxorubicin/ Cyclophosphamide, in breast carcinoma followed by FOLFOX 
regimen in carcinoma colon.  
Alopecia was the frequent specific CADRs occurring in 50.9% and seen 
with Taxanes, Anticancer antiobiotics and Alkylating agents. Second most 
common cutaneous toxicity was Nail pigmentation (45.2%), followed by  acral 
pigmentation (36.7%) and tongue pigmentation (21.6%) with regimen of 
Doxorubin, 5 FU and Capecitabine. It was most commonly seen in patients with 
carcinoma of colon (77.7%) followed by breast carcinoma (52%). Among non 
specific CADRs, dermatophytosis (6.6%) was most commonly observed 
followed by herpes zoster (3.7%) and oral candidiasis (2.8%). 
CONCLUSION: 
Most frequently used regimen was Taxanes/Doxorubicin/ 
Cyclophosphamide and Doxorubicin/ Cyclophosphamide, in breast carcinoma 
followed by FOLFOX regimen in carcinoma colon and they were most 
commonly associated with CADRs. Among regimen with monoclonal 
antibodies, CADRs were less reported. Incidence of cutaneous adverse reaction 
with targeted chemotherapy was proportionately more and severity was also 
high. 
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